ImmunityBio (NASDAQ:IBRX) Director Barry Simon Sells 151,967 Shares

ImmunityBio, Inc. (NASDAQ:IBRX) Director Barry Simon sold 151,967 shares of the business’s stock in a transaction that occurred on Tuesday, January 20th. The shares were sold at an average price of $7.20, for a total transaction of $1,094,162.40. Following the completion of the transaction, the director directly owned 3,091,604 shares of the company’s stock, valued at approximately $22,259,548.80. This represents a 4.69% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.

ImmunityBio Stock Performance

NASDAQ IBRX traded up $0.44 during mid-day trading on Wednesday, reaching $6.92. 95,661,091 shares of the stock were exchanged, compared to its average volume of 33,482,678. ImmunityBio, Inc. has a 1-year low of $1.83 and a 1-year high of $7.98. The business’s fifty day simple moving average is $2.54 and its 200 day simple moving average is $2.52. The stock has a market capitalization of $6.82 billion, a PE ratio of -16.88 and a beta of 0.03.

ImmunityBio (NASDAQ:IBRX) last released its earnings results on Wednesday, November 5th. The company reported ($0.07) EPS for the quarter, topping the consensus estimate of ($0.10) by $0.03. The firm had revenue of $32.06 million during the quarter, compared to analysts’ expectations of $31.88 million. On average, analysts anticipate that ImmunityBio, Inc. will post -0.92 EPS for the current year.

Institutional Investors Weigh In On ImmunityBio

Institutional investors and hedge funds have recently modified their holdings of the stock. Courier Capital LLC raised its position in shares of ImmunityBio by 12.5% in the 2nd quarter. Courier Capital LLC now owns 45,000 shares of the company’s stock valued at $119,000 after purchasing an additional 5,000 shares in the last quarter. Bell & Brown Wealth Advisors LLC grew its position in shares of ImmunityBio by 6.4% during the third quarter. Bell & Brown Wealth Advisors LLC now owns 82,750 shares of the company’s stock worth $204,000 after buying an additional 5,000 shares in the last quarter. Creative Planning increased its stake in shares of ImmunityBio by 9.2% in the second quarter. Creative Planning now owns 62,028 shares of the company’s stock worth $164,000 after buying an additional 5,231 shares during the last quarter. Blair William & Co. IL raised its holdings in ImmunityBio by 2.7% in the second quarter. Blair William & Co. IL now owns 239,814 shares of the company’s stock valued at $633,000 after acquiring an additional 6,314 shares in the last quarter. Finally, Cetera Investment Advisers boosted its stake in ImmunityBio by 56.9% during the 2nd quarter. Cetera Investment Advisers now owns 18,551 shares of the company’s stock valued at $49,000 after acquiring an additional 6,731 shares during the last quarter. Hedge funds and other institutional investors own 8.58% of the company’s stock.

ImmunityBio News Summary

Here are the key news stories impacting ImmunityBio this week:

• Positive Sentiment: FDA discussions gave ImmunityBio a clear path to resubmit an sBLA for ANKTIVA in papillary non‑muscle invasive bladder cancer, and the company plans to submit additional information within 30 days — a direct catalyst for upside. ImmunityBio Stock Soars on FDA Talks for Anktiva sBLA Resubmission
• Positive Sentiment: Company press release confirmed a Type B End‑of‑Phase meeting with the FDA and outlined next steps for ANKTIVA’s sBLA, reinforcing the regulatory-path narrative that investors are rewarding. ImmunityBio Advances Regulatory Discussions with FDA
• Positive Sentiment: HC Wainwright raised its long‑term outlook (FY2030 EPS estimate to $0.68), signaling growing analyst optimism about ImmunityBio’s future earnings power (consensus had been negative).
• Positive Sentiment: At least one independent shop reaffirmed a “buy” and a high price target ($24), which may support further speculative buying interest. Benzinga
• Neutral Sentiment: The stock’s rally has extended over multiple sessions (reported as a 12‑day run in some outlets), driven in part by momentum trading and heavy volume rather than fresh clinical data. ImmunityBio (IBRX) rockets on 12th day, hits fresh high
• Neutral Sentiment: Market coverage notes short‑sellers are under pressure as the rapid share surge forces potential covering — a technical factor that can amplify volatility but isn’t a fundamental guarantee of sustained gains. Stock Market Today, Jan. 21: ImmunityBio Rises Again As Short-Sellers Face Losses
• Neutral Sentiment: Multiple outlets covered the FDA meeting and ensuing price moves; much of the market reaction reflects expectations about the timing and sufficiency of the planned resubmission analyses. ImmunityBio stock soars after FDA meeting on bladder cancer treatment
• Negative Sentiment: Some analysts and commentary warn of momentum risks — advising traders to be cautious or to trim exposure amid a speculative rally and the possibility that regulatory requests could require more data or time than investors expect. Top 3 Health Care Stocks You May Want To Dump In January

Analysts Set New Price Targets

Several analysts have commented on the company. Weiss Ratings restated a “sell (e+)” rating on shares of ImmunityBio in a report on Monday, December 29th. Jefferies Financial Group boosted their target price on shares of ImmunityBio from $8.00 to $9.00 and gave the company a “buy” rating in a report on Friday, December 12th. D. Boral Capital reaffirmed a “buy” rating and set a $24.00 price target on shares of ImmunityBio in a research note on Tuesday. Finally, Piper Sandler lifted their price target on shares of ImmunityBio from $5.00 to $7.00 and gave the company an “overweight” rating in a report on Tuesday. Four analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, ImmunityBio has a consensus rating of “Moderate Buy” and an average price target of $12.00.

ImmunityBio Company Profile

ImmunityBio, Inc is a clinical-stage biotechnology company specializing in the development of novel immunotherapies for cancer and infectious diseases. The company’s research platform centers on harnessing the power of the human immune system—through engineered T cells, natural killer (NK) cells, cytokine superagonists and viral-vectored vaccines—to target and eliminate diseased cells across a range of indications.

Among its lead assets is Anktiva (formerly known as N-803), an interleukin-15 superagonist designed to stimulate NK and T cell activity.